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ABSTRACT
Hoyeraal-Hreidarsson syndrome (HHS) is a severe
form of Dyskeratosis congenita characterized by de-
velopmental defects, bone marrow failure and im-
munodeficiency and has been associated with telom-
ere dysfunction. Recently, mutations in Regulator of
Telomere ELongation helicase 1 (RTEL1), a helicase
first identified in Mus musculus as being responsi-
ble for the maintenance of long telomeres, have been
identified in several HHS patients. Here we show that
RTEL1 is required for the export and the correct cyto-
plasmic trafficking of the small nuclear (sn) RNA pre-
U2, a component of the major spliceosome complex.
RTEL1-HHS cells show abnormal subcellular parti-
tioning of pre-U2, defects in the recycling of ribonu-
cleotide proteins (RNP) in the cytoplasm and splic-
ing defects. While most of these phenotypes can be
suppressed by re-expressing the wild-type protein
in RTEL1-HHS cells, expression of RTEL1 mutated
variants in immortalized cells provokes cytoplasmic
mislocalizations of pre-U2 and other RNP compo-
nents, as well as splicing defects, thus phenocopying
RTEL1-HHS cellular defects. Strikingly, expression of
a cytoplasmic form of RTEL1 is sufficient to correct
RNP mislocalizations both in RTEL1–HHS cells and
in cells expressing nuclear mutated forms of RTEL1.
This work unravels completely unanticipated roles
for RTEL1 in RNP trafficking and strongly suggests
that defects in RNP biogenesis pathways contribute
to the pathology of HHS.
INTRODUCTION
Regulator of Telomere ELongation helicase 1 (RTEL1) was
first identified inMus musculus as being responsible for the
maintenance of long telomeres in embryonic stem (ES) cells
(1). Mouse Rtel1 is involved in telomere replication, but
also in genome wide replication, presumably by facilitating
the progression of the replication fork (2,3). Mouse Rtel1 is
also required for genome stability and repair (4) and the hu-
man protein has been suggested to restrict recombination
through a helicase activity that dismantles recombination
intermediate substrates in vitro (5,6). That human RTEL1
is involved in telomere metabolism has been recently con-
firmed by the identification ofRTEL1mutations in patients
withHoyeraal-Hreidarsson syndrome (HHS), a severe form
of dyskeratosis congenita characterized by short telomeres,
developmental defects, bone marrow failure and immunod-
eficiency (7–11). However, the precise role of humanRTEL1
remains largely speculative.
Based on results obtained from an initially unbiased anal-
ysis of potential human RTEL1 interactors, we set out
to explore the role of this protein in non-coding RNA
metabolism, both experimentally and in the context of
HHS.We discovered that RTEL1 is required for the normal
export of pre-U2 small nuclear (sn) RNA to the cytoplasm
and for its trafficking through that compartment before be-
ing re-imported to the nucleus. U2 is a key component of
the major spliceosome (12). It is transcribed by POLII as
a precursor containing a 3′ extension (13). As soon as this
snRNA is produced, its methylated cap is bound by the cap-
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binding complex, CBC (14), which is in turn bound by an
activated (phosphorylated) form of phosphorylated adap-
tor for RNA export (PHAX) (15). PHAX is a mediator of
snRNA export through its interaction with XPO1 (CRM1)
(15). In the cytoplasm, the ribonucleotide protein (RNP)
export complex dissociates and pre-U2 is transferred to the
survival motor neuron (SMN) complex through its inter-
action with GEMIN5, another cap-binding protein (16).
Once the pre-U2 snRNA is loaded onto the SMN com-
plex, the assembly machine for spliceosomal RNPs (17),
it undergoes maturation through both removal of the last
11–12 nucleotides and trimethylation of its cap, before be-
ing re-imported to the nucleus (17,18). Our results show
that RTEL1 is required for the export of the pre-U2 RNP
complex to the cytoplasm. Furthermore, mutations in the
RING domain of the protein (13), carried by some HHS
patients, are responsible for defects in the cytoplasmic traf-
ficking of the pre-U2RNP. Finally, we show that expression
ofmutated forms ofRTEL1 impact the efficiency of splicing
reactions, in agreement with a defect in U2 RNA biogene-
sis, and which strongly suggests that these defects may be
responsible for at least some of the clinical manifestations
and contribute to the severity of the disease phenotype in
HHS patients.
MATERIALS AND METHODS
Cloning of RTEL1 cDNA and preparations of DNA con-
structs
For mammalian expression FL RTEL1 (nt 1–3903)
was amplified from HeLa cells and was cloned as an
EcoRI/HindIII fragment into pCMV-Tag2B (Stratagene),
which contains an IRES-EGFP inserted as an XhoI/PacI
fragment. The mutant RTEL1 W (eliminating residues
34–48), and the Cter mutant (nt 1–3492) were created
by polymerase chain reaction (PCR) and confirmed by
sequencing (The sequences of primers used are available
upon request). The RING domain was mutated by site di-
rected mutagenesis using the QuickChange kit (Stratagene)
and the primers top: 5′-TGACTTCCAGCGCGGCCAA
GCCGGCTGGCAACGGCA.-3′, bottom: 5′-TGCCG
TTGCCAGCCGGCTTGGCCGCGCTGGAAGTCA-3′;
the amino acid modifications for the mutated RING (mR)
are C1265A and C1268A. Mutating the NLS domain was
done as follows: to generate the mutations R875A, K876A,
K877A PCR was performed with the forward primer
5′-GCGGCCGCGATCCGGCTGGTCAGCCACCC-3′
and downstream primer, and with a reverse primer
5′-GCGGCCGCCCCTCCTCGCGGTTCTTCTGC-3′
and an upstream primer; in the process a NotI site was
created which allowed cloning of the two fragments,
which were then sub-cloned into pCMV-Tag2B containing
RTEL1. For inducible expression the T-REX tetracycline
system (Life Technologies) was used. The constructs were
cloned as EcoRI/XhoI fragments into pcDNA-4/TO.
Other expression plasmids used in this study
pGFP–NES and CY3–polydT20 was a gift from Valerie
Doye.
Anti-hRTEL1 antibody production
Custom rabbit antibodies against purified C-terminal
RTEL1 (last 750aa) were prepared byAGRO-BIO. Immune
sera from two rabbits were obtained and specific antibodies
were affinity purified on NHS-activated sepharose columns
covalently bound to C-terminal RTEL1. Antibody elution
was carried out at acidic pH and antibody solutions were
pH neutralized and stored at −20◦C in 50% glycerol.
Commercial antibodies
The following are other antibodies used in this study:
anti-actin-HRP (horseradish peroxidase) (Santa Cruz,
sc-47778), mouse anti-PCNA (Abcam, ab29), rabbit
anti-XPO1-C-terminal (Santa Cruz, sc-5595), mouse
anti-XPO1-N-terminal (Santa Cruz, sc-136220), mouse
anti-Coilin (Sigma C-1862), mouse anti-XPO5 (Abcam
ab57491), mouse anti-XPOT (Abcam ab49933), rabbit anti-
H3 (Abcam ab1791), mouse anti-GEMIN5 (Santa Cruz,
sc-136200), mouse anti-SMN1 (Abcam, ab5831), goat
anti-LaminB (Santa Cruz, sc-6216), mouse anti-CSE1L
(Santa Cruz sc-135855), rabbit anti-Dyskerin (Santa Cruz
sc-48794), rabbit anti-PHAX (Bethyl, A303–916A), goat
anti-PHAX (M-19) (Santa Cruz, sc-11704), mouse anti-
UBF1 (Santa Cruz sc-13125), mouse anti-nucleolin (Enzo,
ADI-KAM-CP100) mouse anti-TRF2 (Imgenex, IG124A),
mouse anti-XPO5 (Abcam ab57491), mouse anti-NFKB
(Santa Cruz sc-372), mouse anti-RANBP2 (Santa Cruz,
sc-74518), mouse anti-Fibrillarin (Abcam, ab4566), mouse
anti-FLAGM2 (Sigma), IgG mouse (Santa Cruz sc-2025),
mouse anti-coilin (Sigma, C1862), rabbit anti-TCAB1
(Novus, NB100–68252); IgG rabbit (Abcam ab37415). All
Alexa-conjugated secondary antibodies were purchased
from Life Technologies.
Cell lines and culture conditions
All cell lines were cultured in Dulbecco’s modified Eagle’s
medium supplemented with L-glutamine, sodium pyruvate,
non-essential amino acids (Life Technologies) and 10% fe-
tal calf serum (Bio-West). 293T and Hela cells are from
the Institute’s collection. Hela cells stably expressing the
Tet repressor were from Life Technologies. The 293T cell
lines stably expressingRTEL1were established by transfect-
ing pCMV-FLAG- RTEL1-IRES-GFP into these cells fol-
lowed by cell sorting (FACS Vantage, BD) three days later.
A second, clonal sorting was performed 10 days later and
lines stably over-expressing RTEL1 (as determined by west-
ern blot) were isolated. For inducible cell lines, Zeocin re-
sistant cells were obtained and verified by western blot and
immunofluorescence (IF).
Patients’ fibroblast cells and controls
Fibroblasts were obtained from skin biopsies. SV40-
transformed cell lines were obtained as previously described
(19). Informed consent for our study was obtained from the
families in accordance with the Helsinki Declaration. This
study was also approved by the (INSERM) Institutional
Review Board.
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siRNA mediated knockdowns
siRNAs against hRTEL1–1 (GCCUGUGUGUGGAGUA
UGA), hRTEL1–2 (GACCAUCAGUGCUUACUAU),
Luciferase (UCGAAGUAUUCCGCGUACG) or scram-
bled control were synthesized by Life Technologies. Knock-
downs were performed using Amaxa (Lonza) solution R
and program I-013. 200 pmoles of siRNA duplex was used
and cells were left in culture 4–5 days before analysis.
Transfections
Plasmid transfections were carried out using Effectene (Qi-
agen) according to the manufacturers instructions.
Cell treatments
Leptomycin B, ActinomycinD andCyclohexamide (Sigma)
were used as indicated. All lysis buffers contained the anti-
protease N-Ethylmaleimide (Sigma) at 10 mM.
Western blot analyses
For fractionation, cells were treated with Cytoskele-
ton (CSK) buffer (0.5% Triton X-100; 10 mM, 1.4-
piperazinediethanesulfonic acid (Pipes), pH 6.8; 100 mM
NaCl; 300 mM sucrose; 3 mMMgCl2; 1 mMEGTA; 1mM
PMSF) plus protease inhibitor cocktail (Roche). Cells were
incubated on ice for 10 min, then centrifuged at 800 g for
5 min. The supernatant (soluble fraction) was separated
and the pellet (insoluble fraction) was washed once in CSK
and then resuspended in 2× sample buffer. Whole cell ex-
tracts were prepared by adding 2× sample buffer directly
to cell pellets. Proteins were separated in 4–12% sodium
dodecylsulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) gels (Life Technologies) and then transferred to
PVDF membranes (GE Healthcare) for immunodetection.
HRP-linked secondary antibodies (DAKO) were revealed
using chemiluminescent detection (ECL Plus; GE Health-
care).
Immunoprecipitations
Soluble lysates from either 293T, 293T stably overexpress-
ing hRTEL1 or Hela cells, were prepared using NP40 lysis
buffer (50 mM Tris–HCl pH 6.8, 150 mM NaCl, 1% NP-
40, plus protease inhibitor cocktail). Approximately 500 g
of lysates were incubated with 10 g of antibody or non-
specific IgG. RNase A (Invitrogen) 0.1 g/l was added
to indicated lysates for 30 min at 37◦C. Complexes were
bound to protein A or protein G agarose beads (Milli-
pore). Beads were washed 3× with lysis buffer and 2× with
phosphate buffered saline (PBS). Beads were resuspended
in 100 l of 2× sample buffer (0.125 M Tris–HCl, 4% SDS,
20% glycerol, 10% 2-mercaptoethanol, 0.004% bromphenol
blue) and boiled. Proteins were analyzed by western blot.
Liquid chromatography-MS/MS analysis
Soluble lysates from 1.8 × 108 cells, 293T stably overex-
pressing hRTEL1 (ISO2) were prepared using lysing buffer
(50 mM tris pH7.5, 300 mM NaCl, 10% glycerol, 10 mM
Naf, 5 mM glycerophosphate, 5 mM Na pyrophosphate,1
mM B-mercaptoethanol, 0.1% NP40) incubated for 40 min
at 4◦C and homogenized by Dounce and then cleared by
centrifugation at 10 000 g for 30 min. Lysat was incubated
with rabbit anti-RTEL1 antibody covalently attached to
protein A agarose beads or with rabbit preimmun anti-
body overnight at 4◦C. Beads were washed 2× for 2 h with
lysing buffer, and were resuspended in 200 l of 1× sam-
ple buffer (60 mMTris–HCl pH 6.8, 2% SDS, 10% glycerol,
5% 2-mercaptoethanol, 0.004% bromphenol blue). Eluted
proteins were run on a 10% SDS-PAGE gel. In-gel digests
were performed as described in standard protocols. Briefly,
following the SDS-PAGE and washing of the excised gel
slices proteins were reduced by adding 10 mM Dithiothre-
itol (DTT) (Sigma Aldrich) prior to alkylation with 55 mM
iodoacetamide (Sigma Aldrich). After washing and shrink-
ing of the gel pieces with 100% acetonitrile, trypsin (Se-
quencing Grade Modified, Roche Diagnostics) was added
and proteins were digested overnight in 25 mM ammonium
bicarbonate at 30◦C. We achieved peptide concentration
and separation using an actively split capillary HPLC sys-
tem (Ultimate 3000 system, Dionex, Germering, Germany)
connected to the LTQ Orbitrap XLTM mass spectrometer
(Thermo SCIENTIFIC). The mass spectrometer was set
to acquire a single MS scan followed by up to five data-
dependent scan (dynamic exclusion repeat count of 1, repeat
duration of 30 s, exclusion duration of 180 s and lock-mass
option was enabled). The resulting spectra where then an-
alyzed via the MascotTM Software created with Proteome
Discoverer (version: 1.2.0.92, Thermo Scientific) using the
SwissProt Homo sapiens Protein Database (05 September
2012, 20 232 sequences). The resulting Mascot result files
were loaded into the myProMS (20) server for further pro-
cessing. In myProMS we fixed the estimated false discov-
ery rate of all peptide and protein identifications to <1%,
by automatically filtering on peptide length, mass error and
Mascot score of all peptide identifications.
Immunofluorescence
Cells grown on slides or cytospin preparations with 50 000
cells were fixed in Solution F (3% formaldehyde, 1× PBS,
300 mM sucrose) 15 min, when indicated after 5 min pre-
extraction in Solution P (0.5% Triton-X-100, 20 mM Tris-
HCl pH = 8.0, 50 mM NaCl, 5 mM MgCl2, 300 mM su-
crose). Fixed cells were blocked with 10% horse serum in
PBS, incubated sequentially in different primary antibod-
ies, followed by fluorescently labeled secondary antibodies.
All incubation stepswere done in a humid incubator at 37◦C
for 1 h. Slides were mounted in Vectashield with 0.2 g/ml
4′, 6-diamidino-2-phenylindole (DAPI). Images were taken
with a 3D deconvolution microscope (Leica DM6000 B or
Nikon) using the MetaMorph software. Final images are
composed of arithmetic stacks of 20–30 deconvolved im-
ages, each 0.2 m in depth.
RNA FISH
Cells were washed in PBS, fixed for 10 min in 4% formalde-
hyde at RT; after fixation they were washed 2× in PBS for 5
min on ice. Cells were permeabilized with stepwise ethanol
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treatments 70–100%, then re-hydrated in 2× SSC, 25% for-
mamide and pre-hybridized in 1×RHM (10% Dextran sul-
fate (Fluka), 2× SSC (Sigma), 2 mg/ml bovine serum albu-
min, 25% deionized formamide, 10 mMRVC in RNase-free
water), 40 g/ul tRNA (Escherichia coli, Roche), 1 g/ul
N50 (random oligo 50 bp), 1× Ribonucleoside Vanadyl
Complex (NEB)) for 1 h at 37◦C. Probes for four reac-
tions were prepared as follows: 25 ng of biotinylated probe
(pre-U2: CCGGAGGGGGTGCACCGTTCCT) (21); or
CY3-polydT20) was prepared in hybridization buffer (40
g tRNA, Roche, 1 g N50, 25% formamide, 1× RHM,
1× RVC), heated and kept on ice. Slides were hybridized
overnight at 37◦C then washed 2× 20 min in formamide
25%, 2× SSC at 37◦C and 1× in 2× SSC 5 min as described
(21). For revelation, slides were washed at 37◦C and then se-
quentially incubated with Avidin-FITC (1/400 in blocking
solution); biotinylated goat-anti-Avidin (1/100 in blocking
solution); Avidin-FITC (1/400 in blocking solution); and
then washed. Slides were mounted with 0.5 ug/ul of DAPI
and preparations were visualized using 3D deconvolution
microscopy.
RNA analysis
Total RNA was prepared using miRNeasy colums with
DNase digestion (Qiagen). Fractionated lysates were also
prepared according to the manufacturer’s protocol (Qia-
gen). cDNAs were prepared with random hexanucleotide
primers and the SuperScript III system according to the
manufacturer’s protocol (Life Technologies). The mRNA
level was measured by real-time fluorescent quantitative
RT-PCR and amplified using the GeneAmp 7500 sequence
detection system and SYBR Green PCR Kits (Promega).
RNA immunoprecipitations
RNA immunoprecipitations (IPs) were carried out follow-
ing the protocol described by Keene et al. (22), with slight
modifications. Fractionated lysates were obtained by treat-
ing cell pellets with buffer A (10 mM Tris–HCl pH 7.5, 10
mM NaCl, 3 mM MgCl2, 0.05% NP40) on ice for 10 min.
The cytoplasmic fraction was retained after centrifugation.
The pellet was washed 2× in buffer A and lysed in buffer
B (50 mM Tris–HCl pH 6.8, 150 mM NaCl, 1% NP-40)
on ice for 30 min and then cleared by centrifugation. Cy-
toplasm and nulceoplasm lysates were used for RNA-IPs
as follows: approximately 500 g of lysate were incubated
with 10 g of antibody or non-specific IgG for 4 h at 4◦C.
Complexes were incubated with A or G protein beads for 2
h at 4◦C with agitation. After washing, RNA was eluted in
100 mMNaCl, 10 mM Tris–HCl pH 8.0, 10 mM Ethylene-
diaminetetraacetic acid pH 8.0, 1% SDS and treated with
200 g proteinase K for 45 min at 50◦C. Supernatants con-
taining RNA were further using purified RNeasy columns
(Qiagen) and cDNA was prepared as described above.
Northern blot
Fractionated total RNAs were separated using a pre-cast
6% Tris/Borate/EDTA (TBE) Urea gel (Life Technolo-
gies). After electrophoresis, RNAs were transferred onto a
nylon membrane and incubated with 32P-labeled oligonu-
cleotides hybridizing to U snRNAs at 37◦C in ExpressHyb
solution (Clontech). Blots were rinsed 2× SSC 0.1% SDS
briefly, 15 min at 37◦C in 2× SSC 0.1% SDS and then
exposed for 6 h to overnight in a phosphoimaging cas-
sette (Molecular Dymanics). Images were developed us-
ing a STORM 860 phosphoimager (Molecular Dynamics).
The oligonucleotides used were: preU2 (AACACGTTG-
TATCCCCGGTGG); U1 (CCCACTACCACAAATTAT
GC); U2 (TGGAGGTACTGCAATACCAGGT); U4 (GC
CAATGCCGACTATATTGC); U6 (GCTTCACGAATT
TGCGTGTCA); U12 (AAGTAGGCGGGTCACCTTG).
Minigene splicing assay
Cells were transfected with the minicassette plasmid
SXN13 (23) with Effectene (Qiagen). After 48 h, to-
tal RNA was extracted with miRNeasy columns (Qi-
agen) and cDNA prepared using oligo-dT and Super-
script III (Life Technologies). PCR reactions to detect
the splicing products were done using the primers SNXF:
5′-GACCATTCACCACATTGGTG-3′; and SXNRv: 5′-
GAACCTCTGGGTCCAAGG-3′. PCR for specifically de-
tecting partial splice products used SXNF and SXN-
Jrv: 5′-GACCACCAGCAGCCTGGA-3′ or SKNJF: 5′-
GCCCTGGGCAGGTCGAC-3′ and SXNRv. All products
were electrophoresed in a 2% agarose gel.
PCR Primers (Table 1):
Table 1. PCR Primers
tRNA-TYR-F CCTTCGATAGCTCAGCTGGTA;
tRNA-TYR-R TCCTTCGAGCTGGAATCGAACC;
U2-F ATACGTCCTCTATCCGAGGACA;
U2-R TGGAGGTACTGCAATACCAGGT;
pre-U2-R AACACGTTGTATCCCCGGTGG;
U1F ATACTTACCTGGCAGGGGA;
preU1-R GAATAACCCTTATAGGGGAGTC;
U4 GCTTTGCGCAGTGGCAGTA;
preU4-R AAAATTCTCCGTAGAGACTGTCAA;
U12 TGCCTTAAACTTATGAGTAAGG;
preU12-R ACCCCACAGTCAGTCTACTT;
SNHG3-F CTCCTTGGATTTGTTAAGGATTC;
SNHG3-R GTGAAAGAATGTGCATTCCTAGC
U97-F CCCGATGATTATAAAAAGACGCG
U97-R TTGCCCTCATATCTCATAATCTTC
WRN-F CTCCCGTCAACTCAGATATGAGTA
WRN-R TCAGAACCGGGAAAACATCTCCT
RAP1-F ATAGCGGGGAACCACAGAATAAG
RAP1-R ACCACAACCTCCTCAAACTCCC
MAPKAPK2-F TGACCATCACCGAGTTTATGAAC
MAPKAPK2-R AGAACCAAGGCAGAATTCAGTCA
ZNF45-F CCACAGCTCTGTAGCTTCCTAG
ZNF45-R TCCTACTTCTTGAAGAGTCTCC
Statistical analyses
Pearson Chi2 tests were used for percentage comparisons.
RESULTS
RTEL1 localizes at the nucleolus and interacts with exportins
We have developed specific antibodies against RTEL1 (10),
which revealed that both protein isoforms are associated
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with soluble as well as with detergent-resistant cell frac-
tions, with a nuclear predominance and detectable in all
phases of the cell cycle, as well as in all cell types tested (Fig-
ure 1a–c). IF experiments showed that, upon pre-extraction,
RTEL1 displays a pattern of nuclear dots with a fraction
of nuclei (≈20%) showing strong RTEL1 signals associ-
ated with nucleoli, particularly their granular component
(Figure 1d). To further probe this association, we treated
cells with actinomycin D (Act-D), an inhibitor of RNA
polymerases I/II that provokes the redistribution of nucle-
olar components, with enrichment at this compartment of
proteins with RNA-related functions (24,41). Upon Act-D
treatment, RTEL1 was found associated with the nucleolus
in 100% of cells (Figure 1e).
To identify RTEL1 partners and potential functions, we
chose an unbiased approach and performedmass spectrom-
etry analyses after RTEL1 IP using soluble extracts from
293T cells over-expressing RTEL1iso6, the longest isoform
(10). These analyses revealed a large group of proteins in-
volved in RNA metabolism, including the three major ex-
portins XPO1, XPO5 and XPOT (Supplementary Table
S1), all of which are involved in the nuclear export of ncR-
NAs. These interactions were validated in HeLa cells ex-
pressing endogenous levels of all proteins by co-IP using
anti-RTEL1 antibodies (Figure 1f). Also, antibodies against
each of the exportins were able to immunoprecipitate
RTEL1 fromRNase-treated 293T+RTEL1iso6 cell extracts,
indicating that these interactions were RNA-independent
(Figure 1g). Although the interactions of RTEL1 with ex-
portins, as revealed by these IP experiments, appear to in-
volve only a small fraction of both partners, they are likely
specific since antibodies against XPO1, which failed to rec-
ognize RTEL1, even when overexpressed (Supplementary
Figure S1a), were able to immunoprecipitate only a small
fraction of PHAX (Supplementary Figure S1b), the ded-
icated partner of XPO1 for snRNA trafficking and ex-
port (15). Furthermore, IF analyses showed that, in unper-
turbed HeLa cells, RTEL1 and all three exportins are al-
ways found in very close proximity to each other and close
to the nucleolus (Supplementary Figure S1c–e). These co-
localizations are in contrast to the lack of co-localization
between RTEL1 and TRF2 (Supplementary Figure S1f),
a major component of the protein telomere complex and
which was never found in our mass spectrometry analyses.
RTEL1 is part of the pre-U2RNP complex and is required for
the intranuclear trafficking and cytoplasmic export of pre-U2
We decided to explore in more detail the interaction be-
tween RTEL1 and XPO1. XPO1 is critical for the intranu-
clear trafficking and cytoplasmic export of some spliceoso-
mal snRNAs, the best characterized being the precursor of
snRNA U2 (pre-U2), a component of the major spliceo-
some. Given that RTEL1 seemed to interact with XPO1
in an RNA independent manner, we wondered whether
RTEL1 was able to interact with XPO1 when the latter is
part of the pre-U2 RNP export complex. Indeed, antibod-
ies against RTEL1 were able to efficiently immunoprecipi-
tate pre-U2 molecules (Figure 2a). This RTEL1/pre-U2 in-
teraction was completely lost in cells treated with Lepto-
mycin B (LmB), an inhibitor of XPO1 activities (25), in-
dicating that RTEL1 does not bind directly to the RNA
but instead entirely depends on XPO1 for its binding to the
pre-U2 RNP complex (Figure 2a). To at least partially as-
sess the extent of RTEL1 interactions with other exported
U snRNAs, we tested whether anti-RTEL1 antibodies were
able to immunoprecipitate U1 and U4 (two other compo-
nents of the major spliceosome, which are also exported to
the cytoplasm in a XPO1-dependent manner (26–28)), as
well as U12, the equivalent of U2 for the minor form of
spliceosomes and which is expected to follow similar matu-
ration pathways (29,30). As shown in Supplementary Fig-
ure S2a, all three U snRNAs were significantly enriched af-
ter RTEL1 RNA-IP, although at different levels.
The fact that RTEL1 interacts with exportins, and in par-
ticular the pre-U2 RNP complex, suggested that RTEL1
is a factor for nuclear trafficking, cytoplasmic export or
both. Upon transcription, the pre-U2 RNA is bound by
the CBC (31), which in turn is bound by PHAX (15), an
adaptor molecule containing a nuclear export signal (NES).
This NES domain is recognized by XPO1 thus allowing
the formation of the pre-U2 RNP complex, which is then
exported to the cytoplasm (18). While the XPO1 interac-
tion with pre-U2 did not depend on RTEL1 (Figure 2b),
the nucleus/cytoplasm partition of pre-U2 RNAmolecules
was altered in RTEL1-depleted cells, as shown both by RT-
qPCR and by northern blot (Figure 2c and d). Specifically,
we observed an increase in nuclear pre-U2 in comparison
with cytoplasmic pre-U2 in cells depleted for RTEL1, as
shown both byRT-qPCRand by northern blot (Figure 2c, d
and Supplementary Figure S2b). The finding that the levels
of pre-U2-XPO1 RNP increase in the absence of RTEL1,
while confirming that the biogenesis of this RNP does not
depend on RTEL1, is consistent with a failure of the com-
plex to be exported, since once in the cytoplasm, the com-
plex immediately dissociates (16). On the other hand, RNA-
FISH experiments using a specific pre-U2 probe revealed
that, upon RTEL1 depletion, the pre-U2 RNA no longer
accumulated at discrete nuclear foci (previously reported
to be Cajal bodies and sites of pre-U2 processing (32) and
whose formation is dependent on XPO1 (21)), but instead
adopted a diffuse pattern identical to that observed upon
treatment of cells with LmB (Figure 2e). Of note, depletion
of RTEL1 did not prevent the formation of Cajal bodies in
the same cells (Supplementary Figure S2c).
The above experiments establish that RTEL1 interacts
with and is required for the correct intranuclear traf-
ficking and cytoplasmic export of pre-U2 RNP. In con-
trast, RTEL1 is not required for mRNA export, since the
depletion of RTEL1 has no effect either on the overall
cytoplasmic/nuclear partitioning of poly-A mRNAs, as de-
termined by RNA-FISH (Supplementary Figure S2d) or
on the cytoplasmic/nuclear partition of specific mRNAs,
as measured by qRT-PCR (Supplementary Figure S2e). Im-
portantly, the export to the cytoplasm of reporter proteins
carrying an NES is not perturbed upon RTEL1 KDs (Sup-
plementary Figure S2f), indicating that RTEL1 is not in-
volved in the XPO1-dependent, NES-mediated pathway of
protein export.
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Figure 1. Human RTEL1 has a nucleolar localization and interacts with exportins. (a) Antibodies prepared against the C-terminus of the RTEL1iso6
protein specifically recognize both endogenous isoforms of RTEL1. Cells, unperturbed or transfected either with an irrelevant siRNA (si ctrl) or a siRNA
against RTEL1, were lysed with CSK buffer and supernatants (soluble (sol.) proteins) and pellets (detergent-resistant (D-R) proteins) were separated in
SDS-PAGE. PCNAand the ponceau staining of themembrane are shown as loading controls. (b) RTEL1 is expressed in all cells. Both isoforms are detected
at variable levels in different types of human cell lines, as seen in western blots using whole cell extracts. (c) Immunofluorescence staining with anti-RTEL1
and anti-PCNA antibodies indicates that RTEL1 is mostly nuclear and expressed in S as well as in other phases of the cell cycle. Cells were pre-extracted,
fixed with cold methanol and then fixed in PFA (scale bar 10 m). (d) Reinforced signals of RTEL1 in the nucleus are found in around 20% of the cells
associated with the nucleolus (mostly in the granular component) as indicated by co-localizations with three different nucleolar proteins: nucleolin (NCL),
fibrillarin (FBN) and UBF1 (upstream binding factor 1). Coilin, a marker of Cajal bodies, does not colocalize with RTEL1. Cells were pre-extracted and
fixed in PFA (scale bar 5 m). (e) Actinomycin D treatment (50 ng/ml for 3 h) of cells leads to an enrichment of RTEL1 at the nucleolus in 100% of the
cells. This response is similar to that observed with XPO1 (41). Cells were pre-extracted and fixed in PFA (scale bar 5 m). (f) Validation of the interaction
between RTEL1 and exportins in unperturbed HeLa cells (endogenous levels). Input represents 5% of total. (g) The RTEL1 interaction with exportins
does not depend on the presence of RNA. Soluble protein extracts from 293T cells overexpressing RTEL1 were subjected to RNase treatment followed by
IP using antibodies against XPO1, XPO5 and XPOT. Immunoprecipitates were analyzed with anti-RTEL1 antibody. Input represents 5% of total.
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Figure 2. RTEL1 is required for nuclear trafficking and export of pre-U2 to the cytoplasm. (a) The interaction of RTEL1 with pre-U2 is XPO1-dependent.
Antibodies against XPO1 and RTEL1 were used to assess the association of these proteins with pre-U2 by RNA-IP. Antibodies against RTEL1 very
efficiently immunoprecipitated pre-U2 molecules (as measured by RT-qPCR) indicating that RTEL1 is part of the pre-U2 RNP complex. This interaction,
as well as that of XPO1 with pre-U2, is completely lost in cells treated with LmB, indicating that RTEL1 binds to the RNP complex through XPO1 (shown
is the fold enrichment compared to control IgG). Below the histogram is a western blot showing anti-XPO1 IP efficiency in untreated and LmB-treated
cells. Input represents 5% of total. (b) siRNA-mediated depletion of RTEL1 does not alter the formation of the XPO1–RNP complex, as shown by RNA-
IP using anti-XPO1 antibody and measuring the levels of pre-U2 (shown is the fold enrichment compared to control IgG). XPO1 protein levels in the
cell remain unchanged upon RTEL1 depletion (bottom panel). Whole-cell protein extracts were used for western blot analysis and IP 5 days after siRNA
RTEL1 transfection. (c) RTEL1 is required for the export of pre-U2. The concentrations of pre-U2 in the nucleus and the cytoplasm were determined by
RT-qPCR using nuclear and cytoplamic extracts prepared from si ctrl- and si RTEL1-transfected HeLa cells. The levels were normalized to an unaffected
RNA (SNHG3) and then normalized to that ratio in the control. In the absence of RTEL1 pre-U2 becomes enriched in the nucleus and depleted in the
cytoplasm. (d) The relative decrease in the concentration of cytoplasmic versus nuclear pre-U2 in RTEL1 KD cells is confirmed by northern blot analysis.
The EtBr-stained gel before transfer (upper panel) is shown for loading control. The numbers below represent the ratio of nuclear versus cytoplasmic pre-U2
(calculated after normalization for loading). There is relatively more RNA in the nuclear compartment of si RTEL1-treated cells than in cells treated with si
ctrl. (e) RNA FISH experiments using a specific probe against pre-U2 show a nucleoplasmic localization of this RNA with a few stronger foci (presumably
Cajal bodies) in HeLa cells transfected with an si RNA control. Treatment of the same cells with the XPO1-specific inhibitor LmB leads to the elimination
of such nuclear foci. The same phenotype is detected in RTEL1-depleted cells, indicating that RTEL1 is also required for pre-U2 intranuclear trafficking
(scale bar 10 m).
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HHS patients carrying RTEL1 mutations display abnormal
pre-U2 cell distributions
We next examined the pre-U2 status in immortalized fi-
broblasts obtained from HHS patients with mutations in
RTEL1. Strikingly, the lack of nuclear focus formation
by pre-U2 observed in cells experimentally depleted for
RTEL1was also a characteristic of cells fromRTEL1–HHS
patients, where, in addition, pre-U2 molecules were found
to accumulate in large cytoplasmic structures (Figure 3a
and Supplementary Figure S3a). Of note, these large cyto-
plasmic accumulations were also experimentally provoked,
in HeLa cells, by the induced expression of mutated ver-
sions of RTEL1. Specifically, a version carrying a deletion
in the conserved helicase Walker A box domain and an-
othermutant missing the last 150 amino acids of the protein
(called hereafter -Cter) (Figure 3b). The fact that large
cytoplasmic accumulations of pre-U2 RNAs were detected
in RTEL1 patients’ cells (which express at least one mu-
tated RTEL1 isoform, see Supplementary Figure S3b) and
upon forced expression of abnormal RTEL1 versions, sug-
gests that pre-U2 can be exported in the presence of mu-
tated forms of RTEL1; nevertheless, in such a context the
exported molecules appear to be unable to accomplish their
normal cytoplasmic itinerary and therefore accumulate in
that compartment.
RTEL1 is required for the correct cytoplasmic trafficking of
RNP components
Immediately after export, cytoplasmic pre-U2 RNA disso-
ciates from the XPO1–PHAX–CBC complex in a multistep
process that is not completely understood (18). The unload-
ing of the RNA from the exported RNP is necessary for
the loading of GEMIN5, which binds the methylated cap
as well as internal sequences (16,33). This association pro-
motes the recruitment of SMN1, which in turn fosters the
formation of the full Sm core complex thus triggering the
trimethylation of the guanosine cap, the 3′-end trimming of
the RNAand the re-importation of thematuredU2 into the
nucleus (16,18).
We examined the consequences of the RTEL1 dysfunc-
tion on pre-U2 cytoplasmic trafficking by following the as-
sociation of this molecule with GEMIN5. To increase the
sensitivity of GEMIN5 RNA-IPs, we treated cells with cy-
clohexamide, which dissociates GEMIN5 from the Sm core
complex and allows the detection of transient GEMIN5–
RNA intermediates before delivery to SMN1 (16). As ex-
pected because of the observed export defect, depletion of
RTEL1 in HeLa cells led to a decrease in the amount of
pre-U2 that was associated with GEMIN5 in the cytoplasm
(Figure 4a and Supplementary Figure S4a). Intriguingly,
a similar decrease was detected in the RTEL1–HHS cells
(Figure 4a), in spite of the strong pre-U2 accumulation in
the cytoplasm (Figure 3a), suggesting that an intact RTEL1
protein is also required for the correct transfer of the pre-U2
molecule to GEMIN 5 after nuclear export.
Since the transfer of pre-U2 onto GEMIN5, which is
another 7-methylguanosine cap-binding protein (33), re-
quires the unloading of CBC/PHAX from the RNA, we
wished to assess the status of cytoplasmic PHAX in cells
mutated for RTEL1. Depleting cells for RTEL1 led to a
clearly visible abnormal accumulation of PHAX in large
cytoplasmic, DAPI-negative, paranuclear foci, without per-
turbing the distributions of XPO1, RANBP2, GEMIN5 or
SMN1 (Figure 4b). Similar cytoplasmic accumulations of
PHAX have been described upon perturbation of the pro-
cessing of pre-U2 by introduction of a dominant negative
form of SMN1 (34). Interestingly, the expression of WT
RTEL1iso6 (but not that of RTEL1iso6 carrying mutations
in the RING domain) rescued the PHAX phenotype (Fig-
ure 4c, Supplementary Figure S4b–d) in cells depleted for
RTEL1, thus providing direct evidence for the RTEL1 in-
volvement in the recycling of this critical component of the
RNA export pathway. These experiments also revealed the
requirement of an intact RING domain for this particular
function. In addition, the same aberrant PHAX phenotype
was observed both experimentally upon expression of mu-
tated RTEL1 alleles, including RTEL1iso6 mR (Figure 4d
and Supplementary Figure S4e) and in RTEL1-HHS cells
(Figure 4f). Of note, PHAX cytoplasmic accumulations in
RTEL1-HHS cells were rescued by the exogenous expres-
sion ofwild-typeRTEL1iso6 (SupplementaryFigure S4f and
g), thus reinforcing the evidence that RTEL1 mutations in
HHS patients are directly responsible for the phenotype. In
addition, RNA-IP experiments using anti-PHAX antibod-
ies revealed an increased level of association of PHAX with
pre-U2 in the cytoplasm in HHS patients’ cells (Figure 4f),
thus lending support to the idea that, upon export, there is a
failure to transfer the pre-U2 RNA from the CBC–PHAX–
RNP to GEMIN5. On the contrary, and as expected from
the export defect, cells depleted for RTEL1 show a lower
level of PHAX–pre-U2 association in the cytoplasm (Figure
4f). Together, these experiments indicate that in the presence
of a dysfunctional RTEL1 protein, a failure in the transfer
of pre-U2 RNA to GEMIN5 occurs, and the defect is asso-
ciated with a default in the recycling of the exported RNP
component PHAX.
A cytoplasmic form of RTEL1 rescues the cytoplasmic de-
fects in RNP trafficking induced by RTEL1 depletion or by
expression of mutated nuclear RTEL1
Two alternative hypotheses can be envisioned to explain the
effects seen upon expression of mutated forms of RTEL1:
either these proteins promote the export of an abnormal
RNP, which is then not appropriately handled in the cy-
toplasm or RTEL1 is directly required in the cytoplasmic
compartment to help in the pre-U2 transfer. Indeed, the ex-
periments described above suggest that potential RTEL1-
dependent cytoplasmic activities may take place between
the disassembly of the CBC-PHAX-RNP and the transfer
of pre-U2 to GEMIN5.
The RTEL1 protein carries a unique putative nuclear lo-
calization signal (NLS, aa 871–877) immediately after the
helicase domain and right before the recently identified
Harmonin-like domains in the C-terminus (35). Although a
small fraction of RTEL1 can be detected in the cytoplasm,
most of the protein is detected in the nucleus (Figure 1). To
test whether or not RTEL1 has a cytoplasmic role, we de-
signed rescue experiments of cytoplasmic PHAXdefects us-
ing a version of RTEL1 that is confined to the cytoplasmic
compartment. Wemutated the predicted NLS in RTEL1iso6
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Figure 3. Both RTEL1-HHS cells and cells expressing mutated RTEL1 variants display defects in pre-U2 trafficking through the cytoplasm. (a) Pre-
U2 accumulates in the cytoplasm of cells from HHS patients carrying RTEL1 mutations. Specific pre-U2 signals are revealed by RNA-FISH (in white
above/in green below). Arrows point to strong nuclear foci observed in control cells (C) and that are infrequently observed in RTEL1 patient cells (P1 and
P2) (see Supplementary Figure S3a for a quantification). Scale bar 5 m. (b) Expression of mutated forms of RTEL1 lead to pre-U2 mislocalization in the
cytoplasm. Coarse or granular mislocalizations of pre-U2 (in green) are detected by RNAFISH in the cytoplasm of HeLa cells expressing RTEL1 variants
carrying mutations in the Walker domain (W) or, more evidently, when missing the last C-terminal domain (-Cter) (scale bar 5 m).
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Figure 4. Dysfunctional RTEL1 leads to defects in the traffic of RNP components though the cytoplasm. (a) RNA-IPs using cytoplasmic lysates and
anti-GEMIN5 antibodies to detect its interaction with pre-U2 show a deficiency in the formation of the cytoplasmic complex both in RTEL1-depleted
cells (left) and in RTEL1-HHS patients (right) (C: control cells; P1: Patient’s cells). Cells were treated with cyclohexamide. Levels are expressed as fold
enrichment compared to control IgG. Western blot (whole cell extracts) illustrating the level of RTEL1 depletion is shown in Supplementary Figure
S4a. (b) IF experiments using antibodies against PHAX (in green) shows abnormal accumulation of the protein in the cytoplasm of cells depleted for
RTEL1. The localization of other proteins such as XPO1, SMN1, GEMIN5 or RANBP2 (all in red) is not perturbed. Cell preparations were fixed in
PFA without pre-extraction (scale bar 5 m). (c) Induction of expression of RTEL1iso6 in siRNA RTEL1-treated cells counteracts the accumulation of
PHAX in the cytoplasm indicating that the phenotype is due to RTEL1 depletion. HeLa cells carrying a TET-inducible cassette controlling the expression
of WT RTEL1iso6 were transfected with the siRNA RTEL1 or siRNA ctrl and tetracycline was added or not after 4 days for 24 h. Cell preparations were
fixed in PFA without pre-extraction (scale bar 5 m). Western blots (whole cell extracts) confirming the levels of depletion and induction are shown in
Supplementary Figure S4b. A quantification of this experiment is shown in Supplementary Figure S4d. (d) Coarse accumulations of PHAX (in green)
are also detected in HeLa cells induced for the expression of RTEL1 variants carrying mutations in the Walker domain (W), the RING domain (mR)
or missing the last C-terminal domain (-Cter). A quantification of these data is presented in Supplementary Figure S4e. RTEL1 is shown in red (scale
bar 5 m). Cell preparations were fixed in PFA without pre-extraction. (e) Cells from HHS patients (P1 and P2) carrying RTEL1 mutations also show
coarse accumulations of PHAX (shown in green, arrows) in the cytoplasm. Cell preparations were fixed in PFA without pre-extraction (scale bar 5 m).
Quantification of these data is presented in Supplementary Figure S4g. (f) Pre-U2RNA IPs using anti-PHAX antibodies in cytoplasmic lysates. In RTEL1-
HHS patients’ cells (P1), the levels of pre-U2–PHAX complex detected in the cytoplasm is increased, compared to the control fibroblasts (C, left histogram),
whereas the levels of this complex is decreased in RTEL1-depleted HeLa cells, as expected from the export defect, compared to control (right histogram).
Values represent fold enrichment compared to IgG control.
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Figure 5. Acrucial role ofRTEL1 inRNP trafficking occurs in the cytoplasm. Cytoplasmic versions ofRTEL1were created bymutating theNLS consensus
sequence. All NLS-null proteins were flag-tagged allowing its specific detection in IFs (a) and western blots (b). Both approaches confirmed that the NLS
null protein remains cytoplasmic. For IFs, cell preparations were fixed in PFAwithout pre-extraction (scale bar 5 m). ForWestern blot (WB), cytoplasmic
proteins were extracted with CSK buffer. Nuclear proteins were further extracted in the presence of 600 mM NaCl. Compartmentalization was verified
by revealing with antibodies against NFKB (cytoplasmic) and fibrillarin (FBN) (nuclear). (c) An NLS mutated RTEL1iso6 can rescue the cytoplasmic
phenotypes induced by a mutated nuclear form of RTEL1. HeLa cells induced for the expression of RTEL1iso6-mR accumulate PHAX in the cytoplasm.
Exogenous expression of NLS-null RTEL1iso6 is able to eliminate this phenotype. However, NLS-null RTEL1iso6-mR or RTEL1iso1 (which naturally lacks
the RING domain) are not capable of doing this, indicating that the RING domain is crucial for this cytoplasmic activity. Quantitative data can be found
in Supplementary Figure S5b. Cell preparations were fixed in PFA without pre-extraction (scale bar 5 m).
and expressed an N-terminal FLAG tagged version of this
protein exogenously. As expected, the protein was found to
accumulate exclusively in the cytoplasm, both by IF and
by western blot analyses (Figure 5a and b). Expression of
an NLS null RTEL1iso6 protein in cells where expression
of RTEL1iso6 -mR had been induced, completely corrected
the PHAX cytoplasmic accumulations (Figure 5c). Inter-
estingly, an NLS mutated version of the naturally occur-
ring shorter form of RTEL1 (RTEL1iso1, which lacks the
RING domain) was unable to rescue the PHAX phenotype
(Figure 5c). This observation, and the fact that anNLS-null
RTEL1iso6-mR version was also unable to rescue the PHAX
phenotype (Figure 5c and Supplementary Figure S5a), sup-
ports our contention that the RING domain in RTEL1 is
necessary for the correct resolution of cytoplasmic PHAX
intermediates. Finally, NLS null RTEL1 proteins induced
strong cytoplasmic accumulations of pre-U2 in control cells
(Supplementary Figure S5b and c), suggesting that while
nuclear import of RTEL1 is dispensable for PHAX nuclear
reintegration, it is necessary for a correct maturation of pre-
U2 and, likely, nuclear import of U2.
Splicing defects in cells expressing mutated RTEL1 and in
HHS cells
Given that cells expressingmutated forms of RTEL1 lead to
alterations in the biogenesis of U2, a critical component of
the major spliceosome, it would be expected that such cells
will display splicing defects. Using a previously described
(23) exogenous mini-gene splicing assay (Supplementary
Figure S6a), we examined the efficiency of the splicing reac-
tion in 293T cells stably over-expressing a wild-type form of
the RTEL1 protein (either isoform 1 or 6) or overexpress-
ing the -Cter mutated form (Figure 6a), shown above to
induce dramatic perturbations in the cytoplasmic traffic of
pre-U2 RNP. We found that expression of this particular
RTEL1 mutant, but not that of the wild-type form, showed
a reduced splicing efficiency of the mini-gene and also the
accumulation of partially spliced molecules (Figure 6b). A
PCR-based approach (Supplementary Figure S6b), allowed
us to determine that such partially spliced molecules re-
tained the second intron (Figure 6c), thus revealing a spe-
cific failure in the second splicing reaction. Importantly,
HHS cells also displayed similar splicing defects using the
same splicing assay (Figure 6d and e). These experiments
allow us to confirm that the effects of RTEL1 mutations on
U2 biogenesis have a biological impact, notably on splicing.
Finally, since RTEL1 interacts with other POLII-
dependent U snRNAs (shown in Supplementary Figure
S2a) that follow similar PHAX-dependent export and
SMN-dependent cytoplasmicmaturation pathways (26,36),
we wished to determine whether the effect of RTEL1 muta-
tions on splicing efficiency was exclusively explained by its
impact on U2 biogenesis. In fact, northern blot analyses re-
vealed that not only the levels of U2 but those of U1 and
U12 appeared to be reduced in cells overexpressing RTEL1-
-Cter (Supplementary Figure S6c and d), supporting the
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Figure 6. RTEL1 deficiency leads to splicing defects. (a) Western blot showing levels of expression of exogenous RTEL1 proteins in 293T cells (equivalent
amounts of whole cell extracts). (b) Impact of such expressions on the splicing efficiency of introns flanking an exon minicassette. Unperturbed 293T cells,
or 293T cells expressing exogenous RTEL1 proteins were transfected with the minicassette plasmid. After 48 h, RNA was extracted, cDNA prepared and
PCR reactions using the indicated primers (Supplementary Figure S6a) were conducted. Shown are the bands corresponding to the indicated products
(top: unspliced primary transcript, middle: splicing of both introns, bottom: skipping of the middle exon). Cells expressing the C-terminus deleted RTEL1
protein are unable to carry out these reactions efficiently. (c) Accumulation of partially spliced species in 293T cells expressing the C-terminus deleted
RTEL1 protein. A different PCR approach using junction primers (Figure 6b) allowed the detection of partially spliced products that failed to carry out
the second splicing reaction on the same substrate (upper panel). No partially spliced products conserving the first intron are detected (bottom panel).
(d) Splicing deficiencies are also detected in patients’ cells (P1) carrying RTEL1 mutations. (e) These deficiencies are also due to the inability to efficiently
achieve the second splicing event.
idea thatRTEL1 dysfunction impacts spliceosome activities
through perturbation of U snRNA components. Further-
more, RNA IPs using nuclear lysates and PHAX antibodies
showed an increased interaction of this adaptor with pre-
U1 and pre-U12 in HeLa cells depleted for RTEL1 (Sup-
plementary Figure S6e). This last observation is consistent
with the idea that in the absence of RTEL1 there is a gener-
alized defect in the trafficking and export of U snRNPs.
DISCUSSION
In this work, we provide evidence showing that RTEL1 is
required for the nuclear export of the pre-U2 RNP (for a
model, see Figure 7). The mechanism involves a direct in-
teraction of RTEL1 with this RNP in an XPO1-dependent
manner. Whether or not RTEL1 travels with the pre-U2
RNP through the nuclear pore or just licenses it for trans-
port remains to be determined; nevertheless, the large cyto-
plasmic accumulations of PHAX, the XPO1-RNP adaptor,
seen both in the absence and upon expression of mutated
forms of RTEL1 (as well as in RTEL1-HHS patients’ cells),
provide strong evidence that RTEL1 is also exerting a cru-
cial role in the cytoplasm. This view is supported by our
experiments showing that a cytoplasmic form of RTEL1 is
able to rescue such defects.
Although RTEL1 has been shown to be a helicase able
to destabilize recombination DNA intermediates, we do
not know whether this particular activity is relevant to the
phenotypes we observe experimentally or in patients’ cells.
While there is strong genetic evidence to support that this
is a major activity in Caenorhabditis elegans (5), the non-
helicase C-terminal extension of the protein, which com-
prises two harmonin-like domains (35), a PIP box and the
cystein-rich RING domain––often affected by point muta-
tions in HHS patients (7,10), is exclusively found in verte-
brates. Our work clearly indicates that the RINGdomain of
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Figure 7. A model for RTEL1 functions in RNP trafficking. Upon tran-
scription, nascent pre-U2 RNAs are capped and recognized by the cap-
binding complex and by the protein adaptor PHAX. XPO1 interacts with
RNA-bound PHAX through its NES. The production of an RNP com-
petent for export to the cytoplasm requires RTEL1, which binds the com-
plex in an XPO1-dependent manner; RTEL1 is also required for the cor-
rect localization of this complex in Cajal bodies. Immediately upon pass-
ing through the nuclear pore, XPO1 is released from the cargo and PHAX
and CBC must be removed to allow the binding of another cap-binding
protein, GEMIN5. GEMIN5 binding licenses the multistep assembly of
the Sm core complex, leading to maturation of pre-U2 into U2 before the
entire complex is re-imported in to the nucleus. PHAX is also re-imported
into the nucleus likely through a differentmechanism.Ourwork shows that
RTEL1 governs this cytoplasmic step by negotiating the release of pre-U2
from the PHAX RNP and its loading onto GEMIN5. In the absence of
RTEL1, RNA export is prevented and PHAX accumulates in the cyto-
plasm. Expression of RTEL1 mutants that support RNA export leads to
accumulations of RNA and PHAX in the cytoplasm. The RING domain
of RTEL1 appears to be absolutely required to prevent these accumula-
tions. Export deficiency of pre-U2 in RTEL1 depleted cells, or the accu-
mulation of cytoplasmic pre-U2 that cannot be properly utilized both lead
to splicing defects.
RTEL1, which has been so far mostly linked to genome in-
stability phenotypes (7), plays an important role in the cyto-
plasmic function of the protein. Although the link between
a genomic activity and RNP trafficking remains a matter of
speculation, a common molecular mechanism may be in-
voked, possibly a ubiquitin-related protein interaction or
enzymatic activity, as suggested for other proteins contain-
ing similar RING domains such as BMI1 (10,37). Interest-
ingly, the naturally occurring shorter formofRTEL1, which
is devoid of the RINGdomain and which is expressed at the
same level as the longest isoform (10) (this report), fails to
rescue the cytoplasmic defects resulting from RTEL1 defi-
ciency. This observation is in perfect agreement with the fact
that in HHS patients carrying compound heterozygous mu-
tations in RTEL1, one of which only affects the longest iso-
form, the cytoplasmic phenotype is prevalent, even if they
express a wild-type short isoform of the protein.
Considering the facts that RTEL1 interacts with two
other major exportins and that it is not required for protein
or mRNA export, we suggest that RTEL1 is part of a gen-
eral mechanism for non-coding RNA trafficking. Although
further studies are required to address how RTEL1 defi-
ciencies impact microRNA trafficking (which uses XPO5)
or transfer RNA export (which uses XPOT), our results,
using both an experimental system and patients’ cells, in-
dicate that RTEL1 deficiencies do have an appreciable im-
pact on the function of the splicing machinery, most likely
by perturbing the normal cell partitioning and maturation
steps ofRNA spliceosome components, including, butmost
likely not limited to, U2. Indeed, our results suggest that
RTEL1 may be involved in the trafficking and biogenesis of
other POLII-dependent U snRNAs such as U1 and U12,
although the details remain to be explored. Thus, it is ex-
pected that such perturbations, if they are confirmed to exist
in tissues of RTEL1-HHS patients, contribute to the sever-
ity of the clinical manifestations commonly described for
such patients. The characterization of splicing patterns in
RTEL1-HHS patients, in particular in the most affected or-
gans such as the cerebellum, is warranted to clarify this is-
sue.
On the other hand, given the increasingly acknowledged
roles of RNPs in development, organ-specific functions and
disease (38,39), other types of RNP dysfunctions may con-
tribute to both cell proliferation defects and to the clinical
manifestations in HHS. It has been shown that mouse Rtel1
is essential for embryogenesis and mouse ES cells lacking
Rtel1 die upon differentiation (1), clearly indicating that the
protein is involved in functions that are not directly linked
to telomere maintenance since abrogation of telomerase ac-
tivity does not cause immediate embryonic lethality (40).
Whether mouse Rtel1 is also involved in RNP metabolism
remains to be explored.
In conclusion, our work demonstrates that it is possi-
ble to model the biological defects seen in RTEL1-HHS
using an experimental system, thereby allowing the func-
tions of RTEL1 to be further dissected and enabling us to
better understand the connections between telomere biol-
ogy, ncRNA RNP biogenesis, cytoplasmic processes and
disease.
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